Johnson & Johnson to buy Actelion for $30bn
Johnson & Johnson is to acquire Swiss biotechnology company Actelion for $30bn in a complex deal that will see Actelion’s founder heading a standalone spin-off research company based and listed in Switzerland. The world’s largest healthcare company is offering Actelion shareholders $280 per share in an all-cash offer — as well as shares in the new research and development company headed by Jean-Paul Clozel, the Swiss group’s […]